{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:15:41Z","timestamp":1775060141522,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ihj.2018.06.011","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:24:29Z","timestamp":1529349869000},"page":"S96-S100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"S3","title":["Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin"],"prefix":"10.1016","volume":"70","author":[{"given":"Ahmed Mohamed","family":"Abuosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2140-7948","authenticated-orcid":false,"given":"Ayman Hassan","family":"Elshiekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kahekashan","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Burhan","family":"Abrar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona A.","family":"Kholeif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-8720","authenticated-orcid":false,"given":"Abdulhalim Jamal","family":"Kinsara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulwahab","family":"Andejani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel H.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ihj.2018.06.011_bib0005","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2018.06.011_bib0010","first-page":"85","volume":"16","author":"Pfeffer","year":"2009","journal-title":"J Cardiol"},{"key":"10.1016\/j.ihj.2018.06.011_bib0015","first-page":"85","article-title":"Current concepts of anthracycline cardiotoxicity: pathogenesis, diagnosis and prevention","volume":"16","author":"Pfeffer","year":"2009","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.ihj.2018.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ihj.2018.06.011_bib0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2018.06.011_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/187152906779010746","article-title":"Carvedilol: just another beta-blocker or a powerful cardioprotector?","volume":"6","author":"Carreira","year":"2006","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.ihj.2018.06.011_bib0035","first-page":"75","article-title":"The cardioprotective effects of angiotensin converting enzyme inhibitor (perindopril) as prophylaxis of doxorubicin-induced cardiomyopathy\u2014a pilot study","volume":"44","author":"Jaylo","year":"2006","journal-title":"Intern Med Phil J"},{"key":"10.1016\/j.ihj.2018.06.011_bib0040","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/bmj.319.7217.1085","article-title":"Preventing the cardiotoxicity of anthracyclines by dexrazoxane","volume":"319","author":"Hellmann","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ihj.2018.06.011_bib0045","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2018.06.011_bib0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15420\/ahhj.2011.9.2.95","article-title":"Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma","volume":"9","author":"Salehi","year":"2011","journal-title":"Am Heart Hosp J"},{"key":"10.1016\/j.ihj.2018.06.011_bib0055","first-page":"107","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"22","author":"Nagueh","year":"2009","journal-title":"JASE"},{"key":"10.1016\/j.ihj.2018.06.011_bib0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/eurjhf\/hfp199","article-title":"Clinical trials update from the American Heart Association Meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in Heart failure","volume":"12","author":"Cleland","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ihj.2018.06.011_bib0065","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2018.06.011_bib0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/eurjhf\/hfs060","article-title":"Heart rate or beta-bloker dose in patients with chronic heart failure: which is the better target?","volume":"14","author":"Cullington","year":"2012","journal-title":"Eur J Heart Fail"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321731026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321731026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:22:54Z","timestamp":1762176174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001948321731026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":14,"alternative-id":["S001948321731026X"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2018.06.011","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2018.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of Cardiological Society of India.","name":"copyright","label":"Copyright"}]}}